确定埃克西作为一种双向剂,针对SARS-CoV-2 3CL蛋白酶和临床多化合物中的ACE2/S-RBD相互作用
Jiani Lu1, Yan Tang2, Hongtao Li1
1Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
International journal of molecular sciences
|March 13, 2025
概括
像埃克西和本塞拉化等三醇化合物在抑制SARS-CoV-2 3CLpro.中显示出有前途的潜力. 此外,Exifone还可以阻止病毒进入,为抗击COVID-19变种提供新的治疗策略.
科学领域:
- 生物化学和分子生物学
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
背景情况:
- 新兴的SARS-CoV-2变种对当前的COVID-19疫苗和治疗药物产生了抵抗力.
- 多,特别是三,可以抑制SARS-CoV-2 3CLpro,但结构不稳定是一个挑战.
研究的目的:
- 确定已批准或经过临床试验的三醇化合物,可以抑制SARS-CoV-2 3CLpro.
- 评估已识别的化合物对SARS-CoV-2的治疗潜力.
主要方法:
- 文献审查以确定候选三化合物.
- 基于光共振能量转移 (FRET) 的试验,以评估3CLpro抑制.
- 时间依赖的抑制,动力学分析和森化的分子对接.
- 表面等离子体共振 (SPR) 和流动细胞计测试以检测exifone与ACE2和S-RBD的相互作用.
主要成果:
- 埃克西和本塞拉化被确定为SARS-CoV-2 3CLpro抑制剂.
- 班塞拉化被证实是3CLpro.的共价结合剂.
- 埃克西抑制了3CLpro,阻止了ACE2-S-RBD相互作用,并显示了对伪病毒变种的抗病毒活性.
结论:
- 埃克西和本塞拉化为开发新型冠状病毒治疗药物提供了有希望的线索.
- 聚醇提供了一个可行的策略,用于制造保护的3CLpro抑制剂来防止当前和未来的流行病.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.9K
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
33.1K
相关概念视频
00:42Cross-reactivity
30.9K
Overview
30.9K
01:27Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K